Chemomab Therapeutics Ltd. (CMMB)
2.59
-0.10
(-3.72%)
USD |
NASDAQ |
Sep 10, 16:00
2.59
0.00 (0.00%)
After-Hours: 20:00
Chemomab Therapeutics Net Income (Quarterly) : -2.202M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.202M |
| March 31, 2026 | -1.768M |
| December 31, 2025 | -1.885M |
| September 30, 2025 | -1.750M |
| June 30, 2025 | -2.100M |
| March 31, 2025 | -3.306M |
| December 31, 2024 | -2.987M |
| September 30, 2024 | -3.493M |
| June 30, 2024 | -3.618M |
| March 31, 2024 | -3.911M |
| December 31, 2023 | -3.454M |
| September 30, 2023 | -4.068M |
| June 30, 2023 | -7.880M |
| March 31, 2023 | -8.671M |
| December 31, 2022 | -8.250M |
| September 30, 2022 | -8.015M |
| June 30, 2022 | -6.117M |
| March 31, 2022 | -5.115M |
| December 31, 2021 | -5.059M |
| September 30, 2021 | -2.982M |
| June 30, 2021 | -2.780M |
| March 31, 2021 | -1.686M |
| December 31, 2020 | -2.161M |
| September 30, 2020 | -2.468M |
| June 30, 2020 | -3.514M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.541M |
| December 31, 2019 | 9.079M |
| September 30, 2019 | -7.218M |
| June 30, 2019 | -4.434M |
| March 31, 2019 | -9.952M |
| December 31, 2018 | -1.797M |
| September 30, 2018 | -2.631M |
| June 30, 2018 | -5.265M |
| March 31, 2018 | -3.55M |
| December 31, 2017 | -1.956M |
| September 30, 2017 | -1.926M |
| June 30, 2017 | -3.684M |
| March 31, 2017 | -2.303M |
| December 31, 2016 | -1.392M |
| September 30, 2016 | -1.434M |
| June 30, 2016 | -1.155M |
| March 31, 2016 | -0.7735M |
| December 31, 2015 | -1.216M |
| September 30, 2015 | -0.7372M |
| June 30, 2015 | -2.905M |
| March 31, 2015 | -2.634M |
| December 31, 2014 | -1.427M |
| September 30, 2014 | -1.987M |
| June 30, 2014 | -1.307M |
| March 31, 2014 | -1.265M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| BioLineRx Ltd. | -4.414M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 9.262M |
| Can-Fite BioPharma Ltd. | -- |
| Galmed Pharmaceuticals Ltd. | -2.723M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.202M |
| EPS Diluted (Quarterly) | -0.275 |
| Enterprise Value | 12.80M |
| Earnings Yield | -39.40% |
| Normalized Earnings Yield | -39.42 |